224 related articles for article (PubMed ID: 29138117)
21. Phenothiazine normalizes the NADH/NAD
Tapias V; McCoy JL; Greenamyre JT
Redox Biol; 2019 Jun; 24():101164. PubMed ID: 30925294
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
[TBL] [Abstract][Full Text] [Related]
23. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
24. Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.
Bisht R; Kaur B; Gupta H; Prakash A
Neurotoxicology; 2014 Sep; 44():71-9. PubMed ID: 25053526
[TBL] [Abstract][Full Text] [Related]
25. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity.
Hajieva P; Mocko JB; Moosmann B; Behl C
J Neurochem; 2009 Jul; 110(1):118-32. PubMed ID: 19486265
[TBL] [Abstract][Full Text] [Related]
26. Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats.
Karuppagounder SS; Madathil SK; Pandey M; Haobam R; Rajamma U; Mohanakumar KP
Neuroscience; 2013 Apr; 236():136-48. PubMed ID: 23357119
[TBL] [Abstract][Full Text] [Related]
27. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Rai SN; Yadav SK; Singh D; Singh SP
J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
[TBL] [Abstract][Full Text] [Related]
28. Daily consumption of methylene blue reduces attentional deficits and dopamine reduction in a 6-OHDA model of Parkinson's disease.
Smith ES; Clark ME; Hardy GA; Kraan DJ; Biondo E; Gonzalez-Lima F; Cormack LK; Monfils M; Lee HJ
Neuroscience; 2017 Sep; 359():8-16. PubMed ID: 28694175
[TBL] [Abstract][Full Text] [Related]
29. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
31. Melatonin prevents oxidative damage induced by maternal ethanol administration and reduces homocysteine in the cerebellum of rat pups.
Bagheri F; Goudarzi I; Lashkarbolouki T; Elahdadi Salmani M
Behav Brain Res; 2015; 287():215-25. PubMed ID: 25797213
[TBL] [Abstract][Full Text] [Related]
32. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
[TBL] [Abstract][Full Text] [Related]
33. DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats.
Sun SY; An CN; Pu XP
Brain Res Bull; 2012 Sep; 88(6):609-16. PubMed ID: 22664331
[TBL] [Abstract][Full Text] [Related]
34. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective effects of madecassoside in early stage of Parkinson's disease induced by MPTP in rats.
Xu CL; Qu R; Zhang J; Li LF; Ma SP
Fitoterapia; 2013 Oct; 90():112-8. PubMed ID: 23876367
[TBL] [Abstract][Full Text] [Related]
36. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model.
Inden M; Taira T; Kitamura Y; Yanagida T; Tsuchiya D; Takata K; Yanagisawa D; Nishimura K; Taniguchi T; Kiso Y; Yoshimoto K; Agatsuma T; Koide-Yoshida S; Iguchi-Ariga SM; Shimohama S; Ariga H
Neurobiol Dis; 2006 Oct; 24(1):144-58. PubMed ID: 16860563
[TBL] [Abstract][Full Text] [Related]
37. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
[TBL] [Abstract][Full Text] [Related]
38. The effect of dopaminergic neuron transplantation and melatonin co-administration on oxidative stress-induced cell death in Parkinson's disease.
Asemi-Rad A; Moafi M; Aliaghaei A; Abbaszadeh HA; Abdollahifar MA; Ebrahimi MJ; Heidari MH; Sadeghi Y
Metab Brain Dis; 2022 Dec; 37(8):2677-2685. PubMed ID: 36074314
[TBL] [Abstract][Full Text] [Related]
39. Melatonin inhibits manganese-induced motor dysfunction and neuronal loss in mice: involvement of oxidative stress and dopaminergic neurodegeneration.
Deng Y; Jiao C; Mi C; Xu B; Li Y; Wang F; Liu W; Xu Z
Mol Neurobiol; 2015 Feb; 51(1):68-88. PubMed ID: 24969583
[TBL] [Abstract][Full Text] [Related]
40. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
